Recombinant Human CDKN2A/p16INK4a Protein

重组人CDKN2A/p16INK4a蛋白

CCM2 | CDK4 inhibitor p16 INK4 | CDK4I | CDKN2 | CDKN2A | Cell cycle negative regulator beta | CMM2 | Cyclin dependent kinase 4 inhibitor A | Cyclin Dependent Kinase Inhibitor 2A | Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) | Cyclin

rp188347-10μg

10μg

无载体

≥95%(SDS-PAGE)

CDKN2A germline mutations increase the risk of melanoma development. CDKN2A/CDK4 were the first high-penetrance melanoma genes identified. CDKN2A suppresses the initiation of melanoma invasion through inhibition of BRN2. It's a potential prognostic role of CDKN2A/B deletions in early disease stratification in pediatric B-ALL. CDKN2A coding region germline variants are associated with pancreatic adenocarcinoma (PC) susceptibility. Post-translational: Phosphorylation seems to increase interaction with CDK4.

Immobilized Recombinant Human CDKN2A/p16INK4a Protein (rp188347) at 1.0 μg/mL can bind Recombinant CDKN2A/p16INK4a Antibody (Ab095843) with the EC50 of 7.2 ng/mL.

重组表达

16.5 kDa

No tag

14.8 kDa, under reducing conditions; 14.8 & 33.4 kDa, under non-reducing conditions.

E. coli Accession #: P42771 | E. coli

<1.0 EU/μg

人(Human)

2-156 aa

GEPAAGSSMEPSADWLATAAARGRVEEVRALLEAGALPNAPNSYGRRPIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEELGHRDVARYLRAAAGGTRGSNHARIDAAEGPSDIPD

No

Yes